Cilomilast(SB-207499) is among the first of a new generation of PDE4 inhibitors (Ki ¡Ö100 nM). Cilomilast(SB-207499) inhibits HPDE4 and LPDE4 catalytic activity with equal potency (Ki ¡Ö100 nM). SB-207499 and rolipram are equipotent against LPDE4, but Cilomilast(SB-207499) is 100-fold less potent against HPDE4. This profile suggests that Cilomilast(SB-207499) retain the anti-inflammatory activity of rolipram yet have a decreased tendency to produce side effects.

June 21, 2017

prudect name : Cilomilast(SB-207499) is among the first of a new generation of PDE4 inhibitors (Ki ¡Ö100 nM). Cilomilast(SB-207499) inhibits HPDE4 and LPDE4 catalytic activity with equal potency (Ki ¡Ö100 nM). SB-207499 and rolipram are equipotent against LPDE4, but Cilomilast(SB-207499) is 100-fold less potent against HPDE4. This profile suggests that Cilomilast(SB-207499) retain the anti-inflammatory activity of rolipram yet have a decreased tendency to produce side effects.
Cilomilast (SB-207499)

Synonyms: SB-207499CAS NO: 153259-65-5Molecular Formula: C₂₀H₂₅NO₄Molecular Weight: 343.42Purity: 98% minSolubility: In DMSOStorage: −20°C

BMS303141 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508925